Clinical Trial in Dogs for Treatment of Canine Cancers
Sydney, May 2, 2015 AEST (ABN Newswire) - PharmAust Limited ("PharmAust" or "the Company") (
ASX:PAA) is pleased to announce that further to its approval from the Department of Primary Industries (NSW) to amend the current canine trial protocol for the treatment of cancer in dogs (announced 13th April 2015), the first dog treated under the new protocol has demonstrated approximately a 40% reduction in tumour marker p70S6K after only three days of treatment. This is the first evidence that PPL-1 is active in canines by suppressing a tumour marker.
Principal investigator and dog cancer specialist, Dr Angela Frimberger, based at Veterinary Oncology Consultants Pty Ltd and the Animal Referral Hospital in Homebush, NSW said "This is indeed good news and it shows how rapidly PPL-1 imparts an effect on the tumour marker p70S6K. The dog in question was suffering with late stage cancer with limited treatment options. The trial revision for a shorter treatment schedule makes treatment of pets by the owners much easier. It appears that p70S6K in treated dogs is mirroring PharmAust's human trial where there were no adverse events in the low dosage cohort and that p70S6K levels in peripheral blood cells was suppressed."
The US companion pet market sales (est. 2011) are in the region of US$14 billion whilst cancer therapies are estimated at $550 million with a price point of around $1,500 per treatment.
PharmAust's Executive Chairman Dr Roger Aston said "As PPL-1 is already approved for veterinary use by PharmAust's partner, a major global corporation in the Animal Health Industry, we believe that if successful in this trial, PPL-1 will be able to be approved quickly for the treatment of dog cancers following a further pivotal study".
*References:
2011-2012 National Pet Owners Survey Gabelli & Company, Inc. 2004. The US Veterinary health market.
http://www.vet-dc.com/25.html
American pet products manufacturers association, Inc. 2011-2012 National pet owner's survey.
About Pharmaust Limited
PharmAust specialises in the relaunch of existing marketed products for oncology applications making the whole development, regulatory and commercialisation process much faster. In addition, PharmAust's other wholly owned subsidiary, Epichem Pty Ltd generates sales of around $1.7M per annum from contract sales to the pharmaceutical industry of synthetic drugs.
| ||
|
